This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by French, J. A. Articles by Leppik, I. Search for Related Content PubMed PubMed Citation Articles by French, J. A. Articles by Leppik, I. Social Bookmarking                         What's this?

Testing Antiepileptic Drugs In Children

Department of Neurology, Graduate Hospital and the University of Pennsylvania

Ilo Leppik, MD

Department of Neurology and Pharmacy University of Minnesota and MINCEP Epilepsy Care, Minneapolis, MN

Few drugs have been approved by the Food and Drug Administration specifically for the treatment of pediatric patients with epilepsy in the United States. There are many factors that make tests of drugs in this group different from studies among adults. This report reviews issues that must be considered in designing studies that will help bring to market antiepileptic drugs for children. Information on the wide variety of antiepileptic drugs rapidly being developed can only be obtained through well-controlled, well-designed clinical trials. Despite the obstacles and pitfalls, trials among the pediatric population are necessary to establish the unique efficacy and safety profile of each drug and to determine the target population most likely to benefit from each drug. (J Child Neurol 1994;9(Suppl):S26-S32)

Journal of Child Neurology, Vol. 9, No. 1 Suppl, S26-S32 (1994)
DOI: 10.1177/0883073894009001061


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?